STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1826 by analyst upside · 2026-06-27
RLAY
Relay Therapeutics, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+33.7%
implied upside to consensus target
Current Price $18.56
Consensus Target $24.82
Bull Target $32.0
Bear Target $20.0
Analysts Covering 11
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
9
Hold
0
Sell
0
52-Week Low $3.02
52-Week High $18.94
YTD Return +126.9%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E -11.2x
EPS (TTM) $-1.56
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $11M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.02
52-Week High $18.94
Current Price $18.56
Bear Target $20.0
Bull Target $32.0
● Now $18.56 ● Target $24.82
TRADING DATA
Avg Volume 4.1M
YTD Return +126.9%
Analyst Count 11
Consensus Buy
Upside to Target +33.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Relay Therapeutics, Inc. (RLAY) is currently trading at $18.56 with a Wall Street consensus price target of $24.82, implying potential upside of 33.7% over the next 12 months. 11 analysts currently cover RLAY, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $32.0, while the most cautious has a target of $20.0.

RLAY operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 126.9% year-to-date and is currently trading near the upper end of its 52-week range of $3.02 – $18.94.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RLAY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim — Reiterated
Buy → Buy 2026-05-26 62% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-05-26 31% win rate (48 calls)
Barclays — Reiterated
Overweight → Overweight 2026-05-20 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-20 Building track record
Raymond James — Reiterated
Strong Buy → Strong Buy 2026-05-19 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-04-29 31% win rate (48 calls)
Goldman Sachs — Reiterated
Buy → Buy 2026-04-28 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-04-28 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →